首页> 外文期刊>Clinical Immunology, Endocrine & Metabolic Drugs >Liver and Pancreatic Disease in Cystic Fibrosis: Clinics and Drug Therapy
【24h】

Liver and Pancreatic Disease in Cystic Fibrosis: Clinics and Drug Therapy

机译:肝脏纤维化肝癌:诊所和药物治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Abnormal functioning of the Cystic Fibrosis (CF) Transmembrane Conductance Regulator (CFTR) channel impairs muccciliary clearance and promotes chronic bacterial infections in the lung of CF patients. Progressive lung destruction leads to lung failure, the main cause of premature death in CF patients. However, impaired CFTR functioning affects also the pancreas and the liver with well recognized gastrointestinal manifestations that often develop early in life and contribute to the clinical deterioration. Novel therapies are under evaluation in the context of the extensive research on CF liver and gastrointestinal pathophysiology. In this review, pathological mechanisms and clinical manifestations of liver disease and pancreatic insufficiency are described with attention to future therapeutic development.
机译:囊性纤维化的异常功能(CF)跨膜电导调节器(CFTR)通道损害粘液粘连性清除,促进CF患者肺部慢性细菌感染。 进步肺部破坏导致肺部衰竭,CF患者过早死亡的主要原因。 然而,障碍的CFTR功能也会影响胰腺和肝脏,具有良好的胃肠道表现,经常在生命中早期发展并有助于临床恶化。 在CF肝脏和胃肠病理生理学的广泛研究的背景下,新的疗法是评估的。 在本综述中,对未来的治疗发育来说,描述了肝病和胰腺功能不全的病理机制和临床表现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号